Your browser doesn't support javascript.

Biblioteca Virtual en Salud

Hipertensión

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Analysis of permanent brachytherapy combined with maximal androgen blockade in local intermediated-risk prostate cancer / 中华外科杂志

Yi ZHOU; Hanzhong LI; Email: LIHANZHONG@MEDMAIL.COM.CN; Weigang YAN; Zhien ZHOU; Jian CHEN; Zhipeng MAI; Zhigang JI.
Chinese Journal of Surgery ; (12): 257-260, 2015.
Artículo en Zh | WPRIM | ID: wpr-308561
<p><b>OBJECTIVE</b>To evaluate the outcomes of permanent brachytherapy combined with maximal androgen blockade (MAB) in local intermediated-risk prostate cancer.</p><p><b>METHODS</b>From December 2003 to December 2009, 307 patients of local prostate cancer were treated with brachytherapy, 98 cases of intermediated-risk were followed-up for 5 years and data were recorded, aged from 58 to 84 years, average 74 years. Serum PSA was 0.4-19.0 µg/L, average 11.2 µg/L, clinical TNM stage was T1cN0M0-T2bN0M0. Gleason score 4-7, 6.7 in average. Prostate volume ranged from 14 to 65 ml, average 32.1 ml. All the 98 patients underwent permanent brachytherapy combined with MAB. Biochemical recurrence rate, biochemical-free survival, tumor-specific survival, overall survival, salvage therapy and complications were analyzed.</p><p><b>RESULTS</b>Followed up for 5 years, 19 cases had biochemical recurrence, median recurrence period 36 months. One patient died of prostate cancer 45 months after brachytherapy of all 7 patients died in 5 years. Five-years biochemical-free recurrence rate 80.6%, overall survival 92.9%, tumor-specific survival 98.9%, biochemical-free survival 79.3%. Low-urinary tract and rectal irritation symptoms occurred in 75 cases(76.5%). Urinary retention occurred in 7 cases (7.1%) with catheterization duration less than 1 week, no surgical operation were performed. Seeds immigration to lung in 2 cases. No serious complications occurred.</p><p><b>CONCLUSION</b>In local intermediated-risk prostate cancer patients, permanent brachytherapy combined with short-term MAB can be an effective treatment with few complications.</p>
Biblioteca responsable: WPRO